XBIO Stock Forecast: Xenetic Biosciences, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Xenetic Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (78): The share price has been relatively steady.
Value (16): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
XBIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on XBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 20 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 5 Dec 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 22 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 20 Aug 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 16 May 2023 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 11 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | $4.00 |
| 2 May 2022 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $4.00 |
| 11 Jan 2021 | HC Wainwright & Co. | Maintains | Buy | $2.00 → $5.00 |
| 25 Nov 2020 | Ladenburg Thalmann | Initiates | Buy | — |
| 20 Dec 2016 | Ladenburg Thalmann | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
XBIO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
XBIO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Xenetic Biosciences, Inc. returned −39.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
XBIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.1×
- Price / book
- 0.5×
- EV / EBITDA
- —
Cheaper than 63% of US stocks
Cheaper than 87% of US stocks
- Revenue growth (YoY)
- 12.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −81.0%
- Net margin
- −75.9%
Higher than 58% of US stocks
Higher than 15% of US stocks
Higher than 8% of US stocks
- Return on equity
- −47.0%
- Return on assets
- −26.8%
- Dividend yield
- —
Higher than 22% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Xenetic Biosciences, Inc. has a market value of $3.6M.
Revenue in the twelve months to 30 June 2026: $3.3M. The latest quarter grew 12.0% year on year.
Net income over the same four quarters: −$2.5M, a −75.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$2.3M.
Xenetic Biosciences, Inc. employs 2 people — $1.6M of revenue per employee.
Data provided by Twelve Data
XBIO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at XBIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Xenetic Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about XBIO
How does Ticker Nerd's model rank XBIO?
As at 21 Nov 2026, Xenetic Biosciences, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (78 of 100).
What is the XBIO stock forecast for 2030?
No analyst covering Xenetic Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XBIO are extrapolating price history, which says nothing about the business.
How has XBIO stock performed over the past year?
Xenetic Biosciences, Inc. returned -39.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Xenetic Biosciences, Inc. do?
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing immune-oncology technologies for hard-to-treat cancers. The company’s current work centers on its DNase platform, which is designed to target neutrophil extracellular traps (NETs) and support the effectiveness of existing cancer treatments such as immunotherapies.
About Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing immune-oncology technologies for hard-to-treat cancers. The company’s current work centers on its DNase platform, which is designed to target neutrophil extracellular traps (NETs) and support the effectiveness of existing cancer treatments such as immunotherapies. Xenetic Biosciences is also advancing product candidates including XBIO-015 and XBIO-020 for pancreatic carcinoma and other solid tumors, along with platform technologies such as PolyXen and XCart. In addition to oncology, the company has programs that address related therapeutic areas, including anemia in chronic kidney disease through ErepoXen. Headquartered in Framingham, Massachusetts, Xenetic Biosciences serves as a specialized biotechnology player with a pipeline oriented toward novel treatment approaches across oncology and selected adjacent indications.
CEO Mr. James F. Parslow · 2 employees · United States · https://www.xeneticbio.com